This summer the results of Target Ovarian Cancer’s chemotherapy benefit study were published in The Oncologist. Our funding made it possible for UK women to take part in the worldwide study, led in the UK by Dr Anne Lanceley. The study involved women with advanced ovarian cancer, and looked at whether the benefits of continuing with chemotherapy can be assessed so women can make an informed choice about having further rounds of treatment. It ran at 26 study sites across the UK.
The recently published results tell us that asking women about their quality of life and monitoring their general health does help in making decisions about whether to have further chemotherapy, and may help spare some women from unnecessary treatment and chemotherapy side effects in their last months of life. Asking patients about their general health and measuring physical function also improves patient‐doctor communications and helps women considering chemotherapy to make the best decision for them.
Annwen Jones, Chief Executive of Target Ovarian Cancer, said: "We are proud to have been a key funder of this important research into the symptoms benefit of chemotherapy in advanced ovarian cancer, enabling patients in the UK to take part. Research like this is key as it puts women with ovarian cancer first, helping them in their treatment decisions and giving doctors the information they need to provide the best support and treatment experience possible."